Imagine that you are a top executive in a biotechnology firm that has grown rapidly on the basis of its first drug approved by the Food and Drug Administration (FDA). The company has decided to proceed down two new drug development paths while continuing adaptive research on the first drug. It seems appropriate to reorganize in order to accommodate these new strategic initiatives. Discuss the changes you would recommend in organizational structure and explain exactly how you would go about moving from the current structure to the new one. In replies to peers, discuss whether you agree with the strategy presented or not and explain why.